Dapagliflozin in acute myocardial infarction with type 2 diabetes: a randomized clinical trial.
Curr Probl CardiolJul 18, 2026 (epub)
Hilda Elizabeth Macías-Cervantes, Rodolfo Guardado-Mendoza, Luis Jonathan González et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the effects of dapagliflozin on major adverse cardiovascular events in 181 patients with type 2 diabetes post-acute myocardial infarction. At 18 months, the dapagliflozin group had significantly fewer heart failure events (5.3% vs 29.5% in placebo, HR 0.18; p < 0.001) and improved left ventricular ejection fraction.
Key findings
- Heart failure events were significantly lower in the dapagliflozin group (5 events; 5.3%) compared to placebo (26 events; 29.5%).
- The hazard ratio for heart failure events was 0.18 (95% CI, 0.40-0.85; p < 0.001).
- Left ventricular ejection fraction increased by 1.56% in the dapagliflozin group compared to placebo (p = 0.03).
Why it matters
The findings suggest that dapagliflozin may play a crucial role in reducing heart failure risk and improving cardiac function in patients with type 2 diabetes following acute myocardial infarction, potentially influencing treatment strategies in this population.